Fauci: Rules Of Trials/Science Mustn't Slip In Outbreaks

In the midst of a crisis like the recent Ebola outbreak that swept through Guinea, Liberia and Sierra Leone, killing more than 11,300 people and sickening nearly 29,000, it's tempting to just throw everything the medical community has to offer at it in an attempt to save lives – something drug and vaccine makers and others conducting clinical trials often are under public pressure to do in desperate situations.

In the midst of a crisis like the recent Ebola outbreak that swept through Guinea, Liberia and Sierra Leone, killing more than 11,300 people and sickening nearly 29,000, it's tempting to just throw everything the medical community has to offer at it in an attempt to save lives – something drug and vaccine makers and others conducting clinical trials often are under public pressure to do in desperate situations.

But if the principles and rules of science and ethics are not followed, biopharmaceutical companies and researchers engaged in medical product studies could come to the end of an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By 

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.